LAVA Therapeutics (LVTX) Stock Forecast, Price Target & Predictions
LVTX Stock Forecast
LAVA Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a 240.91% upside from LVTX’s last price of $1.76) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
LVTX Price Target
The average price target for LAVA Therapeutics (LVTX) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 240.91% upside from LVTX's last price of $1.76.
LVTX Analyst Ratings
According to 3 Wall Street analysts, LAVA Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for LVTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
LAVA Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 28, 2024 | Arthur He | H.C. Wainwright | $6.00 | $1.88 | 219.15% | 240.91% |
| Mar 20, 2024 | Roger Song | Jefferies | $6.00 | $3.07 | 95.44% | 240.91% |
The latest LAVA Therapeutics stock forecast, released on Jun 28, 2024 by Arthur He from H.C. Wainwright, set a price target of $6.00, which represents a 219.15% increase from the stock price at the time of the forecast ($1.88), and a 240.91% increase from LVTX last price ($1.76).
LAVA Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 2 |
| Avg Price Target | - | $6.00 | $6.00 |
| Last Closing Price | $1.76 | $1.76 | $1.76 |
| Upside/Downside | -100.00% | 240.91% | 240.91% |
In the current month, the average price target of LAVA Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LAVA Therapeutics's last price of $1.76. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 28, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 27, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Sep 16, 2022 | JMP Securities | - | Market Perform | Initialise |
LAVA Therapeutics's last stock rating was published by H.C. Wainwright on Jun 28, 2024. The company gave LVTX a "Buy" rating, the same as its previous rate.
LAVA Therapeutics Financial Forecast
LAVA Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | $2.64M | $15.26M | $468.00K | $1.00M | $1.78M | $921.00K |
| Avg Forecast | $283.48K | $273.37K | $263.63K | $254.23K | $245.17K | $236.43K | $228.00K | $2.17M | $22.91M | $573.05K | $232.32K | $255.97K | $777.17K | $567.37K | $322.64K | $9.26M |
| High Forecast | $283.48K | $273.37K | $263.63K | $254.23K | $245.17K | $236.43K | $228.00K | $2.17M | $22.91M | $573.05K | $232.32K | $255.97K | $777.17K | $567.37K | $322.64K | $11.11M |
| Low Forecast | $283.48K | $273.37K | $263.63K | $254.23K | $245.17K | $236.43K | $228.00K | $2.17M | $22.91M | $573.05K | $232.32K | $255.97K | $777.17K | $567.37K | $322.64K | $7.41M |
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 2 | 1 | - | - | 6 | 6 | 7 | 15 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 11.36% | 59.62% | 0.60% | 1.76% | 5.52% | 0.10% |
LAVA Therapeutics's average Quarter revenue forecast for Jun 23 based on 1 analysts is $573.05K, with a low forecast of $573.05K, and a high forecast of $573.05K. LVTX's average Quarter revenue forecast represents a -78.29% decrease compared to the company's last Quarter revenue of $2.64M (Dec 22).
LAVA Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 2 | 1 | - | - | 6 | 6 | 7 | 15 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | $-4.19M | $-3.86M | $-10.72M | $-10.73M | $-7.13M | $-16.39M |
| Avg Forecast | $-170.09K | $-164.02K | $-158.18K | $-152.54K | $-147.10K | $-141.85K | $-136.80K | $-1.30M | $-13.75M | $-343.83K | $-139.39K | $-7.70M | $-466.30K | $-12.40M | $-193.58K | $-164.80M |
| High Forecast | $-170.09K | $-164.02K | $-158.18K | $-152.54K | $-147.10K | $-141.85K | $-136.80K | $-1.30M | $-13.75M | $-343.83K | $-139.39K | $-6.16M | $-466.30K | $-9.92M | $-193.58K | $-131.84M |
| Low Forecast | $-170.09K | $-164.02K | $-158.18K | $-152.54K | $-147.10K | $-141.85K | $-136.80K | $-1.30M | $-13.75M | $-343.83K | $-139.39K | $-9.24M | $-466.30K | $-14.87M | $-193.58K | $-197.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 30.04% | 0.50% | 22.98% | 0.87% | 36.81% | 0.10% |
undefined analysts predict LVTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LAVA Therapeutics's previous annual EBITDA (undefined) of $NaN.
LAVA Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 2 | 1 | - | - | 6 | 6 | 7 | 15 |
| Net Income | - | - | - | - | - | - | - | - | - | - | $-15.00M | $997.00K | $-7.92M | $-10.55M | $-7.46M | $-16.57M |
| Avg Forecast | $-9.31M | $-11.76M | $-12.38M | $-13.60M | $-8.09M | $-8.75M | $-8.33M | $-5.49M | $-10.72M | $-12.23M | $-15.65M | $-8.07M | $-21.44M | $-12.87M | $-54.30M | $-166.68M |
| High Forecast | $-9.31M | $-11.76M | $-12.38M | $-13.60M | $-8.09M | $-7.50M | $-8.33M | $-5.49M | $33.51M | $-12.23M | $-15.65M | $-6.45M | $-21.44M | $-10.30M | $-54.30M | $-133.35M |
| Low Forecast | $-9.31M | $-11.76M | $-12.38M | $-13.60M | $-8.09M | $-9.75M | $-8.33M | $-5.49M | $-54.96M | $-12.23M | $-15.65M | $-9.68M | $-21.44M | $-15.45M | $-54.30M | $-200.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.96% | -0.12% | 0.37% | 0.82% | 0.14% | 0.10% |
LAVA Therapeutics's average Quarter net income forecast for Dec 22 is $-15.65M, with a range of $-15.65M to $-15.65M. LVTX's average Quarter net income forecast represents a -1669.38% decrease compared to the company's last Quarter net income of $997.00K (Sep 22).
LAVA Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 2 | 1 | - | - | 6 | 6 | 7 | 15 |
| SG&A | - | - | - | - | - | - | - | - | - | - | $3.71M | $3.10M | $3.02M | $4.30M | $3.21M | $1.42M |
| Avg Forecast | $384.17K | $370.48K | $357.27K | $344.54K | $332.25K | $320.41K | $308.99K | $2.94M | $31.05M | $776.62K | $314.84K | $346.90K | $1.05M | $768.92K | $437.25K | $12.55M |
| High Forecast | $384.17K | $370.48K | $357.27K | $344.54K | $332.25K | $320.41K | $308.99K | $2.94M | $31.05M | $776.62K | $314.84K | $346.90K | $1.05M | $768.92K | $437.25K | $15.06M |
| Low Forecast | $384.17K | $370.48K | $357.27K | $344.54K | $332.25K | $320.41K | $308.99K | $2.94M | $31.05M | $776.62K | $314.84K | $346.90K | $1.05M | $768.92K | $437.25K | $10.04M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 11.80% | 8.92% | 2.86% | 5.59% | 7.35% | 0.11% |
LAVA Therapeutics's average Quarter SG&A projection for Jun 23 is $776.62K, based on 1 Wall Street analysts, with a range of $776.62K to $776.62K. The forecast indicates a -79.09% fall compared to LVTX last annual SG&A of $3.71M (Dec 22).
LAVA Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Jun 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Mar 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 | 1 | 1 | 2 | 2 | 1 | - | - | 6 | 6 | 7 | 15 |
| EPS | - | - | - | - | - | - | - | - | - | - | $-0.58 | $0.04 | $-0.31 | $-0.41 | $-0.29 | $-0.65 |
| Avg Forecast | $-0.35 | $-0.44 | $-0.46 | $-0.51 | $-0.30 | $-0.33 | $-0.31 | $-0.20 | $-0.40 | $-0.46 | $-0.58 | $-0.55 | $-0.80 | $-0.37 | $-2.03 | $-8.14 |
| High Forecast | $-0.35 | $-0.44 | $-0.46 | $-0.51 | $-0.30 | $-0.28 | $-0.31 | $-0.20 | $1.25 | $-0.46 | $-0.58 | $-0.55 | $-0.80 | $-0.37 | $-2.03 | $-6.52 |
| Low Forecast | $-0.35 | $-0.44 | $-0.46 | $-0.51 | $-0.30 | $-0.36 | $-0.31 | $-0.20 | $-2.05 | $-0.46 | $-0.58 | $-0.55 | $-0.80 | $-0.37 | $-2.03 | $-9.77 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 0.99% | -0.07% | 0.39% | 1.12% | 0.14% | 0.08% |
According to 0 Wall Street analysts, LAVA Therapeutics's projected average Quarter EPS for Dec 22 is $-0.58, with a low estimate of $-0.58 and a high estimate of $-0.58. This represents a -1558.38% decrease compared to LVTX previous annual EPS of $0.04 (Sep 22).
LAVA Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| BNOX | Bionomics | $0.66 | $6.00 | 809.09% | Buy |
| XLO | Xilio Therapeutics | $0.81 | $7.00 | 764.20% | Buy |
| ANTX | AN2 Therapeutics | $1.06 | $8.75 | 725.47% | Buy |
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| LVTX | LAVA Therapeutics | $1.76 | $6.00 | 240.91% | Buy |
| ACRV | Acrivon Therapeutics | $7.60 | $22.00 | 189.47% | Buy |
| ACHL | Achilles Therapeutics | $0.71 | $2.00 | 181.69% | Buy |
| EWTX | Edgewise Therapeutics | $18.08 | $48.00 | 165.49% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.27 | $6.00 | 164.32% | Buy |
| RZLT | Rezolute | $4.99 | $13.00 | 160.52% | Buy |
| ERAS | Erasca | $2.89 | $7.00 | 142.21% | Buy |
| NXTC | NextCure | $1.38 | $3.00 | 117.39% | Buy |
| ADAG | Adagene | $2.33 | $5.00 | 114.59% | Buy |
| CCCC | C4 Therapeutics | $6.46 | $11.33 | 75.39% | Hold |
| DSGN | Design Therapeutics | $5.77 | $9.67 | 67.59% | Buy |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| TIL | Instil Bio | $64.79 | $78.25 | 20.77% | Hold |
| IKNA | Ikena Oncology | $1.67 | $1.33 | -20.36% | Buy |
LVTX Forecast FAQ
Is LAVA Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, LAVA Therapeutics (LVTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of LVTX's total ratings.
What is LVTX's price target?
LAVA Therapeutics (LVTX) average price target is $6 with a range of $6 to $6, implying a 240.91% from its last price of $1.76. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will LAVA Therapeutics stock go up soon?
According to Wall Street analysts' prediction for LVTX stock, the company can go up by 240.91% (from the last price of $1.76 to the average price target of $6), up by 240.91% based on the highest stock price target, and up by 240.91% based on the lowest stock price target.
Can LAVA Therapeutics stock reach $3?
LVTX's average twelve months analyst stock price target of $6 supports the claim that LAVA Therapeutics can reach $3 in the near future.
What are LAVA Therapeutics's analysts' financial forecasts?
LAVA Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.88M (high $2.88M, low $2.88M), average EBITDA is $-1.728M (high $-1.728M, low $-1.728M), average net income is $-30.657M (high $-29.408M, low $-31.657M), average SG&A $3.9M (high $3.9M, low $3.9M), and average EPS is $-1.143 (high $-1.096, low $-1.18). LVTX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.07M (high $1.07M, low $1.07M), average EBITDA is $-645K (high $-645K, low $-645K), average net income is $-47.058M (high $-47.058M, low $-47.058M), average SG&A $1.46M (high $1.46M, low $1.46M), and average EPS is $-1.754 (high $-1.754, low $-1.754).
Did the LVTX's actual financial results beat the analysts' financial forecasts?
Based on LAVA Therapeutics's last annual report (Dec 2022), the company's revenue was $19.39M, beating the average analysts forecast of $1.83M by 957.98%. Apple's EBITDA was $-33.718M, beating the average prediction of $-20.702M by 62.87%. The company's net income was $-31.907M, missing the average estimation of $-58.026M by -45.01%. Apple's SG&A was $14.12M, beating the average forecast of $2.48M by 468.62%. Lastly, the company's EPS was $-1.23, missing the average prediction of $-2.295 by -46.41%. In terms of the last quarterly report (Dec 2022), LAVA Therapeutics's revenue was $2.64M, beating the average analysts' forecast of $232.32K by 1036.38%. The company's EBITDA was $-4.187M, beating the average prediction of $-139K by 2903.80%. LAVA Therapeutics's net income was $-14.996M, missing the average estimation of $-15.647M by -4.16%. The company's SG&A was $3.71M, beating the average forecast of $314.84K by 1079.64%. Lastly, the company's EPS was $-0.58, missing the average prediction of $-0.583 by -0.57%